Cytori Therapeutics News

News on Cytori Therapeutics (Ticker: CYTX) continually updated from thousands of sources around the net.

Monday Jan 30 | Theflyonthewall.com

Cytori receives approval from FDA to initiate U.S. cardiac cell therapy trial

Cytori Therapeutics has received an Investigational Device Exemption, IDE, approval from the U.S. FDA to begin the ATHENA trial.

Comment?

Related Topix: Healthcare Law, Law, Biotech

Tue Jan 24, 2012

Freshnews

Adipose Stem Cell Heart Attack Trial Data Published in Journal of the ...

The APOLLO trial was a 14-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial evaluating autologous ADRCs extracted with the Company's proprietary Celution System for the treatment of patients suffering from acute myocardial infarction.

Comment?

Related Topix: Biotech

Wed Jan 11, 2012

Seeking Alpha

European Scandal Could Help Cytori Therapeutics

Often, factors outside of a company's control can pound it into the ground or, alternatively, provide an unanticipated boost.

Comment?

Related Topix: Biotech, Breast Enlargement

Sat Dec 31, 2011

Wall St. Cheat Sheet

Healthcare Sector Review: Winning and Losing Stocks on Dec 30th

SIGA Technologies, Inc. : The shares closed at $2.52, up $0.23, or 10.04%, on the day.